Select a Region North America

Access USA

EVERSANA is a proud sponsor of Informa Connect’s Access USA taking place March 20-22 in Philadelphia, Pennsylvania. This year’s co-located event combines Patient Assistance & Access Programs, Hub and Specialty Pharmacy Models East and Rare Disease Innovation & Partnership Summit. Visit our booth or schedule a meeting with EVERSANA’s experts to learn more about our rare disease expertise and next generation HUB and Specialty Pharmacy models that expedite treatment initiation. 

Speaking Sessions Featuring EVERSANA Experts   

On Monday, March 20 at 1:30 PM EST, Skyler Vise, Senior Director, Client & Delivery Excellence, EVERSANA, and Ida Goldstein, Senior Director, Trade, Distribution, and Patient Services, Mirum Pharmaceuticals, will lead a presentation, Improving Patient Experience & Communication for Rare/Ultra-Rare Disease Patients by Leveraging Digital Tools, on the Hubs and Specialty Pharmacy Models East Hub stage. Other key topics will include: 

  • Hear about digital strategies to streamline communication with patients and reduce delays in getting access to specialty medications
  • Explore how digital tools can be used and continually adapted to support patient engagement
  • Learn about how to effectively combine the use of digital tools and personalized interactions with nurse educators to facilitate patient onboarding and improve the patient experience

In addition, EVERSANA’s Kevin O’Meara, Vice President, Patient Services, and Skyler Vise, Senior Director, Client & Delivery Excellence, will present on Patient Assistance for Gene Therapies Tuesday, March 21 at 10:45 AM EST, on the Patient Assistance & Access Programs stage. Key topics will include: 

  • Uncover tools for maintaining patient engagement through the potentially long journey to treatment 
  • Explore gain methods to educate the patient on the process ahead and creating the best experience possible  
  • Look deeper at the role of the patient in their experience in how to utilize patient input 
  • Discuss reimbursement and coverage implications 

About EVERSANA’s Rare Disease Expertise 

With over 7,000 distinct rare and genetic diseases affecting 400+ million individuals, the average time to diagnosis still remains approximately 7 years. In response, EVERSANA has developed innovative, end-to-end strategies to assure patients are identified, diagnosed, onboarded and remain adherent to their treatment plans. 

Rare and orphan drug manufacturers are becoming increasingly aware that new models and new approaches are needed for a successful product launch. With experience in 25 disease states, EVERSANA™ COMPLETE Commercialization is uniquely positioned to remove friction in commercialization to enable an accelerated path to market introduction for critical therapies. Powered by artificial intelligence (AI), machine learning (ML) and Data & Analytics, our end-to-end model supplies predictive analytics to reach patients, improves access to therapy and facilitates positive outcomes.  

By leveraging data and AI capabilities of ACTICS by EVERSANA™ across the patient journey, EVERSANA can predict patient switching behaviors that impact adherence and engagement. This information also powers the optimization of our hub and affordability programs and deploys the “next best action” for each patient, leading to up to a 50% patient adherence improvement over a traditional hub program. 

EVERSANA’s patient services models simplify and expedite the patient journey. Our hub accelerates patient onboarding by supplying real time eligibility determination, self-enrollment with support options, ePa electronic benefit verification (eBV), (ePA), co-pay eligibility and e-prescribing. Our specialty pharmacy model connects patients, providers and payers to offer direct-to-patient dispensing and administration. In addition, data-driven patient profiling can determine customized outreach to provide education and deliver white-glove support to patients, driving brand loyalty and adherence.  

About EVERSANA’s Access and Hub  

EVERSANA’s team of experts leverage technology and automation to reduce access and affordability barriers, simplify onboarding and get patients on therapy faster, ultimately reducing frustrations and driving therapy adoption.  

For example, when a prescriber has selected a given therapy for a patient, several factors can create delays or barriers in getting the patient on therapy including formulary tier status, prior authorization or step therapy requirements, labor-intensive coverage appeals and more. Similarly, the network of specialty pharmacies managing specialty medications has narrowed in recent years. Working with specialty pharmacies to enable swift delivery of prescribed therapies often requires intervention by skilled experts.  

To help streamline the prescribing process, a program with a careful combination of high-tech programs and high-touch support should be implemented with embedded digital tools and easy access to experts who can jump in when needed to help address patient needs.  

Technology-based solutions both automate and streamline repetitive tasks such as digital interventions — which may include electronic benefit verification, streamlined patient enrollment into a product hub, co-pay assistance and more. In addition, many patients and caregivers may have questions or require assistance along their journey to treatment. Having highly trained support resources readily available who can pick up the phone and interact with physicians, payers and specialty pharmacies, can help patients effectively navigate the processes, paperwork and protocols associated with a particular specialty therapy. 

About EVERSANA’s Specialty Pharmacy  

EVERSANA’s deep-rooted connection between hub, specialty pharmacy and direct-to-patient dispensing services allows therapies to be supplied to patients quickly and effectively. Each Specialty Pharmacy program takes a high-touch, white gloves support approach and is individually tailored to best manage inventory, payer relationships, cash flow and wraparound patient service needs. 

Our innovative model begins at the HUB, streamlining onboarding activities and offering support to patients navigating access barriers to ensure their access to therapy. Integrated with our specialty pharmacy program, therapies can quickly be delivered to patients at the necessary site of care, including convenient direct-to-patient dispensing and administration. After patients receive therapies, one point of contact is available for patients to share their experiences and ongoing monitoring and active outreach occurs to promote adherence. 

About Access USA 

Access USA is committed to bringing together the brightest minds and most influential stakeholders shaping the landscape today. Join thought-leaders and potential partners from across the life sciences industry as they dive into the most pressing issues facing the access community right now.  Attendees can expect: 

  • The Brightest Minds and Most Influential Stakeholders in the Access Community 
  • Compelling Discussions 
  • Industry Benchmarking and Tracked Programming for Your Focus Area 
  • Extended Networking Opportunities with Multi-Stakeholders Across Industry 

Visit our booth or schedule a meeting with EVERSANA’s experts today.